• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    GRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions

    Simply Wall St·07/07/2026 00:32:38
    Listen to the news

    GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of securities class action lawsuits.

    See our latest analysis for GRAIL.

    Since that disclosure and the resulting securities class actions, GRAIL’s share price has seen a 14.95% 1 month share price return and a 40.28% 3 month share price return. The 1 year total shareholder return is 53.73%, suggesting recent momentum has picked up after earlier setbacks.

    If you are reassessing your exposure to healthcare and cancer screening, it can help to widen the search to other focused healthcare AI opportunities using the 40 healthcare AI stocks

    After GRAIL’s sharp drop on the trial news and its strong rebound since, the stock now sits slightly above the average analyst target. The key question is where a reasonable view of fair value falls between the recent price action and that range of estimates.

    Most Popular Narrative: 4.5% Overvalued

    GRAIL currently trades at $68.95, slightly above the most followed narrative fair value of $66, which is built using a 7.19% discount rate and detailed earnings and margin assumptions.

    Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.

    Read the complete narrative.

    The core narrative for GRAIL leans heavily on fast revenue expansion, a sharp margin reset and a premium future earnings multiple. Curious what combination of growth, profitability shift and discount rate is needed to support a fair value so close to today’s price and still judge the stock as overvalued?

    Result: Fair Value of $66 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, for GRAIL the narrative can quickly shift if regulatory decisions around Galleri or ongoing securities class action developments begin to weigh on adoption and investor confidence.

    Find out about the key risks to this GRAIL narrative.

    Next Steps

    With sentiment around GRAIL clearly split between concern and optimism, it makes sense to move quickly, review the underlying data, and focus on the 2 key rewards and 4 important warning signs.

    Looking for more investment ideas beyond GRAIL?

    Do not stop at GRAIL alone; broaden your watchlist with other stocks that match clear, data driven criteria so you are not relying on a single story.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.